Disease Progression of Mantle Cell Lymphoma After Ibrutinib Associated with Poor Outcome

Share this content:
Outcome of patients with mantle cell lymphoma who experience disease progression following ibrutinib therapy is poor.
Outcome of patients with mantle cell lymphoma who experience disease progression following ibrutinib therapy is poor.

According to a recent study published in the journal Annals of Oncology, researchers from University of Texas MD Anderson Cancer Center in Houston, Texas, and Peter MacCallum Cancer Center in Melbourne, Australia, have found that the outcome of patients with mantle cell lymphoma who experience disease progression following ibrutinib therapy is poor.

Because there are a substantial number of patients with relapsed/refractory mantle cell lymphoma whose disease is resistant to ibrutinib, researchers sought to investigate the subsequent outcomes of such patients.

For the study, researchers identified 42 patients with a median age of 69 years with mantle cell lymphoma who discontinued ibrutinib treatment due to disease progression, toxicity, elective stem transplant in remission, or withdrawn consent. Patients had received a median of 6.5 cycles of ibrutinib.

RELATED: Minimal Residual Disease Negativity Predicts Prognosis in Mantle Cell Lymphoma

Results showed that among 31 patients who experienced disease progression following ibrutinib and then underwent salvage therapy, the overall response rate was 32% and the complete response rate was 19%.

In addition, the median overall survival among those with disease progression was 8.4 months after a median follow-up of 10.7 months.

Researchers found that elevated serum lactate dehydrogenase at the time of disease progression was associated with decreased overall survival.

Reference

  1. Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015. [Epub ahead of print]. doi: 10.1093/annonc/mdv11

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters